• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Flexion Therapeutics to Present at the Wells Fargo 2021 Virtual Healthcare Conference

    9/3/21 9:00:00 AM ET
    $FLXN
    Major Pharmaceuticals
    Health Care
    Get the next $FLXN alert in real time by email

    BURLINGTON, Mass., Sept. 03, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (NASDAQ:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the Wells Fargo 2021 Virtual Healthcare Conference. The virtual fireside chat is scheduled to begin at 4:35 p.m. ET on Thursday, September 9, 2021.

    To access the live webcast of the presentation, please visit the Flexion website at http://ir.flexiontherapeutics.com.

    About Flexion Therapeutics

    Flexion Therapeutics (NASDAQ:FLXN) is a biopharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of people with musculoskeletal conditions, beginning with osteoarthritis, the most common form of arthritis. The company's core values are focus, ingenuity, tenacity, transparency and fun. Please visit flexiontherapeutics.com.

    Contact:

    Scott Young

    Vice President, Corporate Communications & Investor Relations

    Flexion Therapeutics, Inc.

    T: 781-305-7194

    [email protected]



    Primary Logo

    Get the next $FLXN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $FLXN

    DatePrice TargetRatingAnalyst
    11/19/2021Outperform → Market Perform
    Northland Capital Markets
    10/19/2021$25.00 → $10.00Buy → Neutral
    HC Wainwright & Co.
    10/12/2021$20.00 → $12.00Outperform → Market Perform
    BMO Capital
    10/12/2021Strong Buy → Market Perform
    Raymond James
    10/12/2021$14.00 → $10.00Outperform → Neutral
    Credit Suisse
    8/6/2021$8.00 → $6.00Neutral
    Goldman Sachs
    8/5/2021$20.00 → $18.00Buy
    Needham
    More analyst ratings

    $FLXN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Newtyn Management, Llc

      4 - Flexion Therapeutics Inc (0001419600) (Issuer)

      11/23/21 7:00:12 PM ET
      $FLXN
      Major Pharmaceuticals
      Health Care
    • SEC Form 3: New insider Newtyn Management, Llc claimed ownership of 5,900,000 shares

      3 - Flexion Therapeutics Inc (0001419600) (Issuer)

      11/23/21 6:57:24 PM ET
      $FLXN
      Major Pharmaceuticals
      Health Care
    • SEC Form 4: Stejbach Mark returned $107,364 worth of shares to the company (12,631 units at $8.50), closing all direct ownership in the company to cover taxes

      4 - Flexion Therapeutics Inc (0001419600) (Issuer)

      11/19/21 10:20:34 AM ET
      $FLXN
      Major Pharmaceuticals
      Health Care

    $FLXN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Avilar Therapeutics Appoints Adam Muzikant, PhD, as Chief Business Officer

      Avilar Therapeutics, a biopharmaceutical company focused on extracellular protein degradation, today announced the appointment of Adam Muzikant, PhD, as Chief Business Officer. Dr. Muzikant brings 18 years of business development experience creating and executing value-creating deals, from platform collaborations to commercial-stage product licenses and M&A, across a range of therapeutic areas and technologies at both private and public biopharmaceutical companies. In his role at Avilar, Dr. Muzikant will be responsible for corporate and business development as well as various business operations functions. This press release features multimedia. View the full release here: https://www.busi

      6/15/22 8:00:00 AM ET
      $FLXN
      Major Pharmaceuticals
      Health Care
    • Pacira BioSciences Completes Acquisition of Flexion Therapeutics and Strengthens Leadership Position in Non-Opioid Pain Management

      -- Adds highly complementary ZILRETTA® to Pacira commercial offering -- -- Combined portfolio offers end-to-end non-opioid solutions along the pain pathway -- TAMPA, Fla. and BURLINGTON, Mass., Nov. 19, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced the completion of its previously announced acquisition of Flexion Therapeutics, Inc. (NASDAQ:FLXN). "This is an exciting day for Pacira BioSciences as this acquisition expands our industry leadership and marks a major milestone in our strategy to build a robust offering of novel, non-opioid treatments to im

      11/19/21 8:40:10 AM ET
      $FLXN
      $PCRX
      Major Pharmaceuticals
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Pacira BioSciences to Acquire Flexion Therapeutics Further Expanding Leadership Position in Non-Opioid Pain Management

      -- Adds highly complementary ZILRETTA® to Pacira commercial offering -- -- Combined portfolio offers end-to-end non-opioid solutions along the pain pathway -- -- Further enhances topline revenue growth; provides attractive potential synergies and expected to be accretive to full-year 2022 earnings and significantly accretive thereafter -- -- Pacira to host conference call today at 8:30 AM ET -- TAMPA, Fla. and BURLINGTON, Mass., Oct. 11, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, and Flexion Therapeutics, Inc. (NASDAQ:FLXN) today announced a definitive agreement

      10/11/21 7:00:00 AM ET
      $FLXN
      $PCRX
      Major Pharmaceuticals
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $FLXN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Flexion Therapeutics downgraded by Northland Capital Markets

      Northland Capital Markets downgraded Flexion Therapeutics from Outperform to Market Perform

      11/19/21 8:56:45 AM ET
      $FLXN
      Major Pharmaceuticals
      Health Care
    • Flexion Therapeutics downgraded by HC Wainwright & Co. with a new price target

      HC Wainwright & Co. downgraded Flexion Therapeutics from Buy to Neutral and set a new price target of $10.00 from $25.00 previously

      10/19/21 6:23:51 AM ET
      $FLXN
      Major Pharmaceuticals
      Health Care
    • Flexion Therapeutics downgraded by BMO Capital with a new price target

      BMO Capital downgraded Flexion Therapeutics from Outperform to Market Perform and set a new price target of $12.00 from $20.00 previously

      10/12/21 7:24:34 AM ET
      $FLXN
      Major Pharmaceuticals
      Health Care

    $FLXN
    SEC Filings

    See more
    • SEC Form 15-12B filed by Flexion Therapeutics, Inc.

      15-12B - Flexion Therapeutics Inc (0001419600) (Filer)

      11/29/21 4:15:36 PM ET
      $FLXN
      Major Pharmaceuticals
      Health Care
    • SEC Form EFFECT filed by Flexion Therapeutics, Inc.

      EFFECT - Flexion Therapeutics Inc (0001419600) (Filer)

      11/26/21 12:15:07 AM ET
      $FLXN
      Major Pharmaceuticals
      Health Care
    • SEC Form S-8 POS filed by Flexion Therapeutics, Inc.

      S-8 POS - Flexion Therapeutics Inc (0001419600) (Filer)

      11/19/21 9:29:02 AM ET
      $FLXN
      Major Pharmaceuticals
      Health Care